Treatment of bleeding with low half-life fibrinogen
AssigneeLaboratoire Francais Du Fractionnement Et Des Biotechnologies
InventorsFrank Pieper, Anurag Relan, Erik Jordahl Forsberg
Life of this patent
Estimating the term…
Abstract
The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.
Claims26
-18. (canceled)
A pharmaceutical composition comprising:
- (a) recombinant human fibrinogen having a half-life of less than 12 hours;
- (b) factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin;
- and
- (c) a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition comprising:
- (a) recombinant human fibrinogen;
- (b) factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin;
- and
- (c) 0-4 moles sialic acid per mole fibrinogen.
A method of treating or effecting prophylaxis in a human patient who is bleeding or is at risk of bleeding, comprising administering to the patient a dose of recombinant human fibrinogen having a reduced half-life relative to natural human plasma fibrinogen, wherein the dose delivers a peak plasma concentration of recombinant and endogenous fibrinogen greater than 1 g/L.
A method of treating or effecting prophylaxis in a human patient who is bleeding or is at risk of bleeding, comprising administering recombinant fibrinogen having a reduced half-life relative to natural human plasma fibrinogen to the patient, wherein the fibrinogen is under-sialylated.
A pharmaceutical composition comprising recombinant human fibrinogen having a half-life of less than 2 days, and a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition comprising recombinant human fibrinogen and 0-6 moles sialic acid per mole fibrinogen.
Dependencies are inferred from the claim text.